13F reference period
Q2 2026
Security Snapshot
Parabilis Medicines, Inc. - Common Stock, $0.0001 par value (PBLS) Institutional Ownership
CUSIP: 698955101
13F Institutional Holders and Ownership History from Q2 2026 to Q3 2026
Institutions Reporting
79
Shares (Excl. Options)
98.97M
Full value: 98,966,433 · shares · 30 Jun 2026Price
$27.37
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- PBLS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 98,966,433
- Total 13F value
- $2,710,461,855
- Portfolio coverage rank
- 0.02%
- Share change
- +96,669,886
- Value change
- +$2,647,752,089
- Number of holders
- 79
- Shares outstanding
- 120,995,849
- SEC-reported price per share
- $26.85
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- PBLS - Parabilis Medicines, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 698955101.
- 79 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- The headline uses Q2 2026 reported holdings.
- Quarter-over-quarter comparison is unavailable because the immediately preceding quarter is missing.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 79 institutions filings for Q2 2026.
Security key
698955101
13F reference period
Q2 2026
13F holders
79
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
PBLS full holder history
Parabilis Medicines, Inc. SEC filings
Parabilis Medicines, Inc. company facts
Parabilis Medicines, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 698955101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
PBLS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 24% | 28,933,371 | RA Capital Management, L.P. | 11 Jun 2026 | ||||
| FMR LLC | 8.5% | $304,973,738 | 10,292,735 | FMR LLC | 30 Jun 2026 | |||
| ARCH Venture Fund XII, L.P. | 5.3% | $190,010,671 | 6,412,780 | ARCH Venture Fund XII, L.P. | 30 Jun 2026 |
As of 30 Jun 2026,
79
institutional investors reported holding
shares of
Parabilis Medicines, Inc. - Common Stock, $0.0001 par value (PBLS).
This represents
82%
of the company’s total
outstanding shares.
98.97M
Full value: 98,966,433 · shares · 30 Jun 2026121M
Full value: 120,995,849 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
77%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 24% | 28,933,371 | 6.9% | $791,906,364 | |
| FMR LLC | 8.5% | 10,292,735 | 0.01% | $281,712,158 | |
| ARCH Venture Management, LLC | 5.3% | 6,412,780 | 16% | $175,517,789 | |
| venBio Partners LLC | 4.4% | 5,266,697 | 28% | $144,149,497 | |
| Alphabet Inc. | 4.1% | 4,919,498 | 0.14% | $134,646,660 | |
| Nextech Invest Ltd. | 3.9% | 4,663,176 | 6.1% | $127,631,127 | |
| Cormorant Asset Management, LP | 3.8% | 4,615,612 | 6.5% | $126,329,300 | |
| REGENERON PHARMACEUTICALS, INC. | 3.4% | 4,166,666 | 64% | $114,041,648 | |
| Siren, L.L.C. | 2.5% | 2,992,259 | 1.7% | $81,898,129 | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2% | 2,368,200 | 0.38% | $64,817,634 | |
| Jupiter Topco LLC | 1.9% | 2,296,547 | 0% | 0.03% | $62,709,766 |
| Frazier Life Sciences Management, L.P. | 1.6% | 1,920,805 | 1.1% | $52,572,433 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.6% | 1,880,704 | 0.54% | $51,474,868 | |
| General Catalyst Group Management, LLC | 1.3% | 1,600,937 | 23% | $43,817,646 | |
| GENERAL ATLANTIC, L.P. | 1.3% | 1,538,461 | 1.4% | $42,107,678 | |
| Soleus Capital Management, L.P. | 1.2% | 1,465,070 | 1.4% | $40,098,966 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.1% | 1,302,479 | 0% | $35,648,850 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.96% | 1,156,962 | 0% | $31,666,050 | |
| JPMORGAN CHASE & CO | 0.86% | 1,042,772 | 0% | $30,438,515 | |
| Foresite Capital Management VI LLC | 0.83% | 999,044 | 4.3% | $27,343,834 | |
| Catalio Capital Management, LP | 0.68% | 824,043 | 4.2% | $22,554,057 | |
| ALLIANCEBERNSTEIN L.P. | 0.67% | 810,279 | 0.01% | $22,177,336 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.62% | 751,947 | 0% | $20,581,000 | |
| Casdin Capital, LLC | 0.53% | 645,690 | 0.88% | $17,672,535 | |
| Venrock Adviser, LLC | 0.52% | 625,000 | 0.52% | $17,106,250 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Headline period
Q2 2026
Rows shown
1-2 of 2